Internal Medicine, Hematology & Oncology · Los Angeles, CA
NPI
1962509216
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
Cedars-Sinai Medical Center 8700 Beverly Boulevard, C-2000
Los Angeles, CA, 90048
Phone (310) 423-1825
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.8M
89,389 services
Medicare patients, 2024
424
Average age 74
Drug cost, 2024
$12.1M
1,866 prescriptions
Company payments, 2025
$139K
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert A Vescio was code J9144 (injection, daratumumab, 10 mg and hyaluronidase-fihj), 41,220 times for 19 patients. In total Robert A Vescio billed 89,389 services in 63 codes, and Medicare paid $2.8M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-09-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 41,220 | 19 | $39.25 | $1.6M |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 5,350 | 14 | $35.77 | $191K |
| 99214 Office E&M - Established | Facility | 667 | 245 | $77.41 | $52K |
| 36415 Venipuncture Blood Collection | Office | 319 | 52 | $8.65 | $2,759 |
| 96401 Chemotherapy Administration | Office | 263 | 22 | $66.00 | $17K |
| 99215 Office E&M - Established | Facility | 204 | 108 | $119.54 | $24K |
| 96366 Intravenous Infusion, Hydration | Office | 179 | 15 | $18.34 | $3,283 |
| 99443 Telephone Services | Facility | 165 | 93 | $81.95 | $14K |
| 99214 Office E&M - Established | Office | 157 | 55 | $108.38 | $17K |
| 96375 Injection Administration | Office | 157 | 15 | $13.93 | $2,188 |
| 96365 Intravenous Infusion, Hydration | Office | 130 | 21 | $57.77 | $7,510 |
| 99232 Hospital E&M - Subsequent | Facility | 103 | 35 | $66.60 | $6,860 |
| 96372 Injection Administration | Office | 99 | 11 | $12.32 | $1,220 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 84 | 13 | $0.62 | $52.18 |
| 99233 Hospital E&M - Subsequent | Facility | 72 | 25 | $100.81 | $7,258 |
By year: 2022 $2.4M for 83,641 services; 2023 $2.6M for 93,750 services; 2024 $2.8M for 89,389 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 319 | 52 | $8.65 | $2,759 |
Medicare prescription drug claims, 2024
In 2024, the drug Robert A Vescio prescribed most often to Medicare patients was Revlimid (Lenalidomide), with 187 prescriptions and refills. In total Robert A Vescio wrote 1,866 Medicare prescriptions that cost $12.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Revlimid Lenalidomide | 187 | 188 | 25 | $3.7M |
| Lenalidomide Generic | 151 | 151 | 28 | $2.1M |
| Pomalyst Pomalidomide | 121 | 121 | 21 | $2.6M |
| Acyclovir Generic | 89 | 191 | 36 | $1,638 |
| Dexamethasone Generic | 73 | 129 | 31 | $1,465 |
| Valacyclovir Valacyclovir Hcl | 64 | 160 | 27 | $3,922 |
| Ninlaro Ixazomib Citrate | 63 | 63 | Under 11 | $710K |
| Oxycodone Hcl Generic | 60 | 60 | Under 11 | $845 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 59 | 59 | Under 11 | $1,234 |
| Venclexta Venetoclax | 51 | 51 | Under 11 | $462K |
| Morphine Sulfate Er Morphine Sulfate | 47 | 47 | Under 11 | $1,911 |
| Vyndamax Tafamidis | 44 | 52 | Under 11 | $1.1M |
| Zolpidem Tartrate Generic | 35 | 44 | Under 11 | $85.24 |
| Pantoprazole Sodium Generic | 32 | 48 | Under 11 | $313 |
| Brukinsa Zanubrutinib | 31 | 31 | Under 11 | $408K |
Brand drugs: - claims; generic drugs: 1,213 claims; opioid claims: 252.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robert A Vescio $139K ($138K in general payments such as food, travel and fees and $950 for research) from 9 companies. The largest payer was Janssen Biotech, Inc. with $73K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 70 | $73K |
| E.R. Squibb & Sons, L.L.C. BMY | 16 | $23K |
| Regeneron Healthcare Solutions, Inc. REGN | 6 | $13K |
| Amgen Inc. AMGN | 6 | $8,657 |
| Alnylam Pharmaceuticals Inc. ALNY | 7 | $7,039 |
| Karyopharm Therapeutics Inc. KPTI | 6 | $6,945 |
| Pfizer Inc. PFE | 4 | $4,607 |
| Kite Pharma, Inc. GILD | 2 | $1,530 |
| Janssen Scientific Affairs, LLC JNJ | 5 | $262 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.